Trial record 19 of 36 for:
stargardt
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02402660 |
Recruitment Status :
Recruiting
First Posted : March 30, 2015
Last Update Posted : May 5, 2020
|
Sponsor:
Alkeus Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Alkeus Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | December 2021 |
Estimated Study Completion Date : | March 2022 |
Publications: